Commercial
MPIssuedDate
  
MPNewsFlashTopicPub
MPNFSortOrder
  
MPPolicyPageName
  
MPPurposePub
Title
  
MPPageName
  
1/25/2021
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for AmeriHealth New Jersey Members (Updated January 25, 2021)
0

The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for AmeriHealth New Jersey members.
 
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for AmeriHealth New Jersey Members (Updated January 25, 2021)ed926941-fa2e-4d39-9eac-bb629c419742
1/25/2021
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) For AmeriHealth Pennsylvania Members (Updated January 25, 2021)
0

The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for AmeriHealth Pennsylvania members.
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) For AmeriHealth Pennsylvania Members (Updated January 25, 2021)64ce2b02-a79a-400b-9eb8-b341b4cc8093
1/25/2021
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) For AmeriHealth Pennsylvania Members (Updated January 25, 2021)
0

The purpose of this communication is to provide advance notice regarding information and procedure codes related to testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) for AmeriHealth Pennsylvania members.
Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) For AmeriHealth Pennsylvania Members (Updated January 25, 2021)4011cf53-a501-412c-a759-fd9034deb24f
1/19/2021
Coverage of the COVID-19 Vaccination for AmeriHealth Members (Updated January 19, 2021)
0.1
The purpose of this communication is to provide notice regarding information and procedure codes related to the coverage of SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) vaccines and administration of the vaccines for AmeriHealth members.​​​
Coverage of the COVID-19 Vaccination for AmeriHealth Members (Updated January 19, 2021)1823b90d-a9f2-4382-ab46-c5b79b289d6c
1/18/2021
Telemedicine Services for AmeriHealth Pennsylvania Members (Updated February 10, 2021)
0.1
The purpose of this document is to provide advance notice regarding coverage for telemedicine services for our AmeriHealth Pennsylvania members in response to Coronavirus Disease 2019 (COVID-19).
Telemedicine Services for AmeriHealth Pennsylvania Members (Updated February 10, 2021)a74c165b-c97f-413c-98cb-53563d43c910
1/4/2021
1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Products
0
The intent of this document is to communicate Commercial Product coverage determinations for services identified through the Annual Code Update process. 
1/1/2021 CPT & HCPCS Annual Code Update Coverage Determinations for Commercial Productse9ec2c0c-fb3f-4dc8-ba77-76f1d77bff75
12/30/2020
​Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of AmeriHealth New Jersey Members (Updated December 30, 2020)
0

The purpose of this document is to communicate the Company's coverage position for Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 treatment of AmeriHealth New Jersey members. 

This communication addressing Treatments for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) is effective from October 22, 2020 through March 31, 2021 through the duration of the state of emergency and public health emergency as described in Executive Order 103.

This document includes the following updates to the version that was published on November 25, 2020:

  • The name of this communication was changed FROM Veklury® (remdesivir) and Bamlanivimab® (LY-CoV555) for COVID-19 Treatment TO Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment.
  • Combination of Olumiant® (baricitinib)) and Veklury® (remdesivir) for COVID-19 Treatment, including coverage statement, was addressed per FDA Emergency Use Authorization (EUA) for this combination therapy.
  • Combination of Casirivimab/Imdevimab for COVID-19 Treatment, including coverage statement and procedure codes, was addressed per FDA EUA for this combination therapy.​

 
Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of AmerHealth New Jersey Members (Updated December 30, 2020)78e407fa-9a24-4426-9486-3cdfa2f1d696
12/30/2020
​Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of AmeriHealth Pennsylvania Members (Updated December 30, 2020)
0

The purpose of this document is to communicate the Company's coverage position for Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 treatment of AmeriHealth Pennsylvania members. 

This communication addressing Treatments for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)) is effective from October 22, 2020 through March 31, 2021, or for the duration of the public health emergency.​​

This document includes the following updates to the version that was published on November 25, 2020:

  • The name of this communication was changed FROM Veklury® (remdesivir) and Bamlanivimab® (LY-CoV555) for COVID-19 Treatment TO Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment.
  • Combination of Olumiant® (baricitinib)) and Veklury® (remdesivir) for COVID-19 Treatment, including coverage statement, was addressed per FDA Emergency Use Authorization (EUA) for this combination therapy.
  • Combination of Casirivimab/Imdevimab for COVID-19 Treatment, including coverage statement and procedure codes, was addressed per FDA EUA for this combination therapy.


Veklury® (remdesivir) (including in combination with Olumiant® (baricitinib)), Bamlanivimab® (LY-CoV555), and Casirivimab/Imdevimab for COVID-19 Treatment of AmerHealth Pennsylvania Members (Updated December 30, 2020)ec8b335e-9976-4006-ac49-82561f19e2a7
11/25/2020
​Notice of Withdrawal of Advance Notification of Future Policy #00.10.41h: Telemedicine Services​ (AmeriHealth Pennsylvania)
0
The purpose of this communication is to provide notice that Advance Notification of future Policy​ #00.10.41h: Telemedicine Services (AmeriHealth Pennsylvania)​ has been withdrawn from the Medical Policy Portal.​
Notice of Withdrawal of Advance Notification of Future Policy #00.10.41h: Telemedicine Services488be3d7-9066-4c5c-9823-d18ec61c663e
10/1/2020
10/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Products
1
The intent of this article is to communicate Commercial Product coverage determinations for services identified through the Quarterly Code Update process. The procedure codes that represent these services will become effective on 10/1/2020, unless otherwise noted.

For more information related to these services, please refer to specific policies when applicable.​

10/1/2020 CPT & HCPCS Quarterly Code Update Coverage Determinations for Commercial Productsc1c57826-12dd-47cc-b303-2102ee13691a
1 - 10Next